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Cross-reactivityLegionella pneumophila is responsible for Legionnaires' disease (LD). Its detection in both environmental and clin-
ical samples is mainly performed by culture plate method which requires up to 10 days to obtain results. Now-
adays, there are commercial antibodies against this bacterium, but they have not been tested against all
subgroups of L. pneumophila sg 1 or serogroups 1–16 or their cross-reactions with other non-Legionella bacteria.
Indeed,manyof these antibodies becameavailablewhenonly 8 serogroups of L. pneumophilahad beendescribed.
We tested 7 antibodies and found that 2 (Mab 8/5 and OBT) speciﬁcally detected all the subgroups of
L. pneumophila sg 1, one without cross-reactions (Mab8/5). Moreover, the LP3IIG2 antibody detected almost all
serogroups tested with lower rates of cross-reactivity, resulting in a speciﬁc sensitive antibody for the detection
of L. pneumophila. LP3IIG2 presented higher rate of cross-reactivity against respiratory non-Legionella isolates,
thereby contraindicating its clinical applicability.34-934-978-654.
Sabrià).© 2017 Elsevier Inc. All rights reserved.1. Introduction
Legionella is a Gram-negative bacterium ubiquitous in fresh water
habitats (Null, 1996). Legionella can colonize man-made water systems
and be dispersed by aerosols generated by showers, faucets, cooling
towers, whirlpool spas, and fountains. The inhalation and
microaspiration of Legionella (Sabria and Yu, 2002) by susceptible peo-
ple can cause Legionnaire's disease (LD), which is manifested as pneu-
monia, presenting a case fatality rate of 10% (http://ecdc.europa.eu/en/
publications/Publications/legionnaires-disease-2015.pdf), or a mild
nonpneumonic febrile illness called Pontiac fever (Kaufmann et al.,
1981). Legionella pneumophila contains at least 16 serogroups, but
serogroup 1 (sg 1) accounts for the majority of European and
American clinical isolates (Yu et al., 2002).
Urinary antigen test is the gold standard to detect L. pneumophila in-
fections due to the speed and simplicity of this test. However, it only de-
tects L. pneumophila sg 1 cases, producing a diagnostic blind spot for LD
caused by L. pneumophila non-sg 1 and Legionella spp. Although more
diagnostic tools are available, only 5 immunodiagnostic methods
(Alere BinaxNOW® Legionella; http://www.alere.com/en/home/prod-
uct-details/binaxnow-legionella-urinary-antigen-eia.html; http://
www.meridianbioscience.com/diagnostic-products/respiratory/tru/
tru-legionella.aspx; http://www.sascientiﬁc.com/news-events/8-news/5-legionella-test; http://www.trinitybiotech.com/products/legionella-
urinary-antigen-eia/) have been approved for commercial purposes by
the US Food and Drug Administration (http://www.fda.gov/).
Legionella genus-speciﬁc (Helbig et al., 1995b; Steinmetz et al.,
1991) and L. pneumophila species-speciﬁc (Goldstein and Gosting;
Gosting et al., 1984; Helbig et al., 1995b; Hindahl and Iglewski, 1986;
Rockey et al., 1996) antibodies were described and evaluated decades
ago. Since then, 8 new serogroups have been described, and a larger
number of antibodies have been commercialized without much infor-
mation about the speciﬁcity.
The objective of this study was to determine the speciﬁcity of 7 an-
tibodies against L. pneumophila (subgroups of sg 1 and serogroups),
Legionella species, and cross-reactions. Thus, the use of an already vali-
dated antibody is the most adequate way to achieve the speciﬁcity of
all L. pneumophila serogroups to be applied in an environmental and/
or clinical detection tool.
2. Materials and Methods
2.1. Bacterial Isolates
Weused 79 L. pneumophila and non-L. pneumophila bacterial isolates
obtained from different sources: American Type Culture Collection
(ATCC), environmental water samples (E), and respiratory samples
(R). Legionella microorganisms were grown on BCYE for 72 h, and
non-Legionella environmental isolates were grown on Tryptic Soy Agar
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ry isolates for 24 to 72 h.
Bacterial characterizationwas performedby 16S rRNAgene ampliﬁca-
tion and sequencing using the universal primers E27 forward
(AGAGTTTGATCMTGGCTCAG) and B530 reverse (CCGCGGCKGCTGG
CAC). Furthermore, Legionella species were identiﬁed by ampliﬁcation
and sequencing of themip gene (Ratcliff et al., 1998). Sequencingwas per-
formed by the Genomics Core Facility at the Germans Trias i Pujol Re-
search Institute.
2.2. Antibodies
Seven antibodies were tested: Mab 8/5 (Dresden Panel), Mip 1
(MBS855187, MyBiosource, San Diego, CA), Mip 2 (MBS852400,
MyBiosource), Omp 28 (MBS852640, MyBiosource), LP3IIG2 (ATCC
HB-8472), OBT (OBT0943P, AbDserotec, Bio-Rad, Hercules, CA), Bac-
Trace (01-90-03, SeraCare, Milford, MA). Secondary antibodies were
used with nonconjugated antibodies. Anti-mouse conjugated with
horseradish peroxidase (HRP) (ab97265, Abcam, Cambridge, UK) was
used to detect Mab 8/5, Mip 1, Mip 2, and Omp 28; anti-rabbit HRP
(ab97200, Abcam) was used to detect KPL; and anti-mouse conjugated
with ﬂuorescein-5-isothiocyanate (FITC) (F0257, Sigma-Aldrich Co., St.
Louis, MO) was used in the immunoﬂuorescence assay (IFA) test.
LP3IIG2was obtained from the hybrid cell line HB-8472 (ATCC). This
hybridoma was cultured, puriﬁed, and HRP conjugated by the Antibody
Service of Universitat Autònoma of Barcelona.
2.3. Adjusting Antibody Concentration
The working concentration of each antibody was determined using
an isolate of L. pneumophila sg. 1 subgroup Philadelphia (reference iso-
late) according to the protocol described below.
2.4. Antibody Assay
The antibodies were screened with an in-house enzyme-linked im-
munosorbent assay (ELISA) test using Legionella and non-Legionella iso-
lates as a capturing antigen. Bacterial suspensions were prepared in
phosphate-buffered saline (PBS) pH 7.2 and adjusted to an optical den-
sity (OD) of 0.3 at awavelength of 625 nm(~108 CFU/mL). One hundred
microliters of these bacterial suspensions was added to a 96-well plate
(Nunc Brand, Denmark) and was dried overnight at 40 °C. These plates
were stored dried at 4 °C until use. The plates were blocked with 10%
fetal bovine serum in PBS for 2 h at 37 °C. One hundred microliters of
the primary antibody was added to each well and incubated for 1 h at
37 °C. Then, the plates were washed three times with 0.05% Tween 20
in PBS (PBS-Tween). For nonconjugated antibodies, the plates were in-
cubated with a secondary HRP-conjugated antibody for 1 h at 37 °C and
washed 3 times with PBS-Tween. Developing reaction was performed
with 50 μL 3,3′,5,5′-Tetramethylbenzidine (TMB, Sigma) during
20 min at room temperature in the dark. The reaction was stopped
with 50 μL of 1 N H2SO4, and the colorimetric reaction was measured
at OD 450 nm using a Varioskan Flash (Thermo Electron Corporation).
Each test was performed in duplicate in the experiment and in trip-
licate on different days.
2.5. Indirect Immunoﬂuorescence Assay
Bacterial suspensions were prepared in PBS or in 1% formalin and
adjusted to an OD of 0.3 at a wavelength of 625 nm, and employed as
antigen for indirect IFA. LP3IIG2 was used as a primary antibody and
the anti-mouse FITC as a secondary antibody. Results were observed
in a Fluorescence Microscope (Axioscope, Zeiss, Germany) and were
classiﬁed as positive if they reacted strongly.2.6. Data Analysis
The ELISA background value was calculated for each isolate accord-
ing to the antibody used. For primary conjugated antibodies, the back-
ground value was determined as the signal obtained from the
antibodywithout bacteria. For antibodies that required a secondary an-
tibody, the background value was determined as the signal obtained
from the bacteria with secondary antibody, without the primary anti-
body. After the subtraction of the background value, all the results
were normalized using the value obtained with the reference isolate in-
cluded in each experiment as an internal control. The detection limit
was established for each antibody as themean (X) plus 3 times the stan-
dard deviation (SD) obtained in the background test: Mab 8/5 (0.25),
Mip 1 (0.25), Mip 2 (0.25), Omp 28 (0.25), LP3IIG2 (0.19), Bac-Trace
(0.5), and OBT (0.11). Results were expressed as positive (+), negative
(−), or inconclusive (−/+) (discrepancies among replicates). OD
values (mean and SD) were shown in Supplementary material.
The studywas performed in 2 different steps. Seven antibodies were
ﬁrst evaluated at a working concentration according to the protocol de-
scribed. The antibodies were screened in this ﬁrst trial, and according to
the results obtained, the test was repeated increasing the number of iso-
lates tested.
3. Results
3.1. Antibody Assay
The reactivity of 7 antibodieswas tested to 19 Legionella isolates and
14 non-Legionella isolates (Table 1). First, the antibodies were checked
to select only those that reactedwith L. pneumophila isolates, discarding
the non-speciﬁc L. pneumophila antibodies.
The Mab 8/5 (1:200) was described to exclusively recognize
L. pneumophila sg 1 as described elsewhere (Helbig et al., 1995a), and
it did not present any cross-reaction.
The 2monoclonal antibodies against theMip protein (Mip 1: 5 ng/μL
and Mip 2: 10 ng/μL) did not react against some L. pneumophila
serogroups or some subgroups of L. pneumophila sg. 1. Furthermore,
Mip 2 showed even less reactivity against the L. pneumophila serogroups
than Mip 1 (Table 1).
The monoclonal Omp 28 antibody (5 ng/μL) showed high reactivity
to almost all the isolates tested (L. pneumophila and non-Legionella),
with higher values in non-Legionella isolates.
The polyclonal OBT antibody (20 pg/μL) reacted with all the isolates
of L. pneumophila sg 1 and showed reactivity with L. pneumophila sg 13
and some cross-reactions with environmental isolates.
The polyclonal Bac-Trace antibodywas adjusted to 2 pg/μL. This con-
centration was lower compared to the other antibodies. Bac-Trace
showed a low rate of positive results against Legionella isolates
(L. pneumophila sg 1 Philadelphia, L. pneumophila sg 9 and sg 15) and
cross-reacted against 7 out of 14 environmental isolates.
The LP3IIG2 antibody (2.5 ng/μL) showed speciﬁcity against all the
serogroups of L. pneumophila and cross-reactions against L. micdadei
and Sphingomonas spp.
Only 2 of the 7 antibodies tested, OBT and LP3IIG2, were selected to
test their reactivity against 47 more isolates (26 Legionella and 21 non-
Legionella environmental and respiratory isolates) (Table 2). We chose
LP3IIG2 due to their sensitivity in front of all L. pneumophila serogroups
tested. OBT andMab8/5 showed a speciﬁc recognition of L. pneumophila
sg 1, but OBT showed incongruent results regarding previous publica-
tions (Yanez et al., 2005), so we decided to carry out the second step
in the ELISA tests also with this antibody to characterize it.
The LP3IIG2 antibody reacted against all the subgroups of
L. pneumophila sg 1 (except the 2 Benidorm and 1 Camperdown iso-
lates) and 1 isolate of L. pneumophila sg 4, 6, 8, and 10 (Table 2). Regard-
ing the L. non-pneumophila isolates, this antibody only recognized
L. micdadei. Testing the environmental non-Legionella isolates, this
Table 1
Reactivity in the ﬁrst step of the ELISA test with 7 L. pneumophila antibodies (+ for positive results,− for negative results, and−/+ for discrepancy between replicates).
Isolates (ref)a Sourceb Mab 8/5
(1/200)c
Mip 1
(5 ng/μL)c
Mip 2
(10 ng/μL)c
Omp 28
(5 ng/μL)c
LP3IIG2
(2.5 ng/μL)c
Bac-Trace
(2 pg/μL)c
OBT
(20 pg/μL)c
Legionella isolates
Lp 1 Philadelphia (A) E + + + + + + +
Lp 1 France (A) E + + − + + − +
Lp 1 OLDA(A) E + − − + + − +
Lp 1 Oxford (A) E + + + + + − +
Lp 3 E − − − + + − −
Lp 8 (A) E − − + + − − −
Lp 9 (A) E − + + + + + −
Lp 10 (B) 43283 − + − + + − −
Lp 11 43130 − − − − + − −
Lp 12 (A) E − + + + −/+ − −
Lp 12 (B) 43290 − + − + + − −
Lp 13 43736 − + − + + − −/+
Lp 14 (B) 43703 − + − + + − −
Lp 15 E − + − + + + −
L. micdadei E − + + + + + +
L. parisiensis (A) E − − + + − + −
L. anisa 35292 − + − + − − −
L. dumofﬁ 35850 − + + + − − −/+
L. gormani 33297 − + − + − + −
Non-Legionella isolates
Aeromonas veronii E − + + + − + −/+
Sphingomonas spp. E − + + + + + −
Delftia spp. E − + + + − + −/+
Stenotrophomonas acidanimiphila E − + + + − − +
Paenibacillus dendritiformis E − − + + − − −
Ochrobactrum E − + − + − − −
Bacillus spp. (A) E − − − + − + −
Bacillus spp. (B) E − + + + − + −
Bacillus spp. (C) E − − − + − − −
Pseudomonas aeruginosa (A) E − + + + − + −
Chryoseobacterium spp. E − − − − −/+ − −
Bacillus licheniformis E − − + + − − −
Serratia spp. E − − − + − + −
Acetinobacter spp. E − − + + − − −
Lp = Legionella pneumophila.
a Indicates the local laboratory number in order to differentiate isolates.
b E = environmental water source; reference number for ATCC source.
c Concentration of the antibody.
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sive result was obtainedwith Chryoseobacterium spp. (positive and neg-
ative results in the replicates). LP3IIG2 showed high cross-reactivity
against 9 out of 20 respiratory isolates belonging to 4 different bacterial
species (Staphylococcus aureus, Neisseria spp.,Moraxella catharralis, and
Haemophilus parainﬂuenzae).
The OBT antibody showed a high speciﬁcity versus all the subgroups
of L. pneumophila sg 1 (Table 2). OBT cross-reacted against L. micdadei,
with inconclusive results against L. pneumophila sg 13 and L. dumofﬁ.
Testing the environmental non-Legionella isolates, this antibody only
cross-reacted with Stenotrophomonas acidanimiphila, and inconclusive
results were obtained with Aeromonas veronii and Delftia spp. OBT
showed cross-reactivitywith 7 respiratory isolates belonging to 3 differ-
ent bacterial species (Staphylococcus aureus, Neisseria spp., and
Moraxella catharralis).
3.2. Indirect Immunoﬂuorescence Assay
All the L. pneumophila isolates (n= 11) with negative result in the
LP3IIG2 antibody assay were conﬁrmed as negative by IFA (Fig. 1). Re-
sults obtained in IFA test showed no differences between samples pre-
pared in PBS or formalin.
4. Discussion
In the last 30 years, the number of L. pneumophila serogroups has
doubled, and the number of commercialized antibodies hasexponentially risen. However, the information available about their re-
activity is limited (reactivity against Legionella and other cohabitant
species). It is necessary to make efforts to validate the reactivity of
these antibodies to establish which ones are speciﬁc to L. pneumophila
serogroup 1, to L. pneumophila non-sg 1, and to Legionella non-
pneumophila and cross-reactivity with other bacterial species.
The antibodies tested in this studydidnot present ahigh speciﬁcity and
sensitivity to L. pneumophila. However, 3 antibodies showed promising re-
sults. Mab 8/5 and OBT showed reactivity to L. pneumophila sg 1, although
Mab 8/5 had higher speciﬁcity (it did not present any cross-reaction).Mab
8/5 recognized the lipopolysaccharide (LPS), the main conserved domain
in L. pneumophila sg 1 (Helbig et al., 1995a). On the other hand, the OBT
also presented this sensitivity to L. pneumophila sg 1, albeit with a lower
speciﬁcity, because it also reacted with some non-Legionella isolates.
LP3IIG2 was designed against the mompS protein and showed the
best sensitivity/speciﬁcity ratio. Fluorescein-conjugated LP3IIG2 anti-
body is commercially available, and it detects almost all the serogroups.
However, contrary to a previous study (Goldstein and Gosting), it did
not react with some of the isolates belonging to different
L. pneumophila serogroups (1, 4, 6, 8, and 10) or with some respiratory
isolates. It is important to note the variability observed in the results ob-
tained with isolates of the same serogroup. These discrepancies ob-
served were conﬁrmed with another technique (IFA) using 2 sample
preparations. Membrane changes due to treatment with formalin did
not improve the results obtained in the IFA.
LP3IIG2 was the most sensitive antibody tested against
L. pneumophila. Moreover, negative results obtained with
Table 2
Reactivity in the second step of the ELISA test with the LP3IIG2 and OBT antibody versus
Legionella, environmental and respiratory isolates (+ for positive results,− for negative
results and−/+ for discrepancy between replicates).
Isolates (ref)a Number isolates Sourceb LP3IIG2
(2.5 ng/μL)c
OBT
(20 pg/μL)c
Legionella isolates
Lp 1 Knoxville 2 E + +
Lp 1 Philadelphia 2 E + +
Lp 1 Benidorm 2 E − +
Lp 1 France (A) 1 E + +
Lp 1 France (B) 1 E −/+ +
Lp 1 OLDA 2 E + +
Lp 1 Oxford 2 E + +
Lp 1 Bellingham 2 E + +
Lp 1 Heysham 2 E + +
Lp 1 Camperdown (A) 1 E −/+ +
Lp 1 Camperdown (B) 1 E − +
Lp 3 1 E + −
Lp 3 ST93 1 E −/+ −
Lp 4 (A) 1 E − −
Lp 4 P 1 E + −
Lp 6 1 E − −
Lp 8 (A,C) 2 E − −
Lp 8 (B) 1 E + −
Lp 9 3 E + −
Lp 10 (A) 1 E − −
Lp 10 (B) 1 43283 + −
Lp 11 1 43130 + −
Lp 12 (A) 1 E −/+ −
Lp 12 (B) 1 43290 + −
Lp 13 1 43736 + −/+
Lp 14 (A) 1 E −/+ −
Lp 14 (B) 1 43703 + −
Lp 15 1 E + −
L. micdadei 1 E + +
L. parisiensis 3 E − −
L. anisa 1 35292 − −
L. dumofﬁ 1 35850 − −/+
L. gormani 1 33297 − −
Lp = Legionella pneumophila.
a Indicates the local laboratory number in order to differentiate isolates.
b E = environmental water source; R = respiratory source; reference number for
ATCC source.
c Concentration of the antibody.
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speciﬁc L. pneumophila sg 1 antibody such asMab 8/5. The LP3IIG2 anti-
body would only be useful for environmental detection if a thorough
validation is performed because it only presented 1 clear cross-
reaction (Sphingomonas spp.). Regarding clinical detection, neither
LP3IIG2 nor OBT would be suitable because of the low speciﬁcity of
these antibodies.
This work highlights the relevance of the need for validation studies.
Indeed, a large number of antibodies are now available in the market,
but information regarding the reactivity of most of these antibodies is
limited. Several antibodies against different proteins (mip, momps,Fig. 1. LP3IIG2 indirect immunoﬂuorescence assay. A: L. pneumophila sg 1 Philadelphia (C
L. pneumophila sg 8 is shown as an example of the results obtained with all the isolates testedHsp60) have shown to be Legionella genus or L. pneumophila species spe-
ciﬁc (Gosting et al., 1984; Helbig et al., 1995b; Hindahl and Iglewski,
1986). However, most of these antibodies are not yet commercially avail-
able. In this respect, several antibodies against the previously described
proteins have been produced, with the manufacturer only performing
the validation step at protein recognition and not to differential epitope
recognition. Three of the antibodies ruled out in the present study
corresponded to this type of antibody (Mip1, Mip2, and Omp 28).
These results reinforce the importance of a good design in the pro-
duction of antibodies. A protein may contain a species-speciﬁc epitope,
but if the antibody produced is not speciﬁcally designed against this epi-
tope rather than against the whole protein, we may obtain antibodies
that are not species speciﬁc, having a good sensitivity but not speciﬁcity,
hence the importance of a validation process after the production of
antibodies.
Other speciﬁc antibodies have been described. However, they pres-
ent some caveats. A genus-speciﬁc epitope was described on the heat
shock protein (Steinmetz et al., 1991). Nonetheless, the expression of
this epitope was lower in the membrane, making it unsuitable for our
experiment. The 53-3D12 antibody (Barthe et al., 1988) has been de-
scribed to speciﬁcally recognize a common epitope on the LPS of
L. pneumophila sg 1–8, but this antibody is not commercially available,
and information about its cross-reactivity is lacking.
The major limitation of this study is that the results of the validation
cannot be extrapolated to other immunological techniques, and addi-
tional cross-reactions cannot be ruled out.
In conclusion, in the present study, we evaluated several antibodies
for rapid identiﬁcation of L. pneumophila, but only 2 (Mab 8/5 and OBT)
are suitable for the speciﬁc recognition of L. pneumophila sg 1 and only 1
(LP3IIG2) for the speciﬁc recognition of all the serogroups of
L. pneumophila. LP3IIG2 shows compatible results to be applied in the
speciﬁc L. pneumophila detection in water samples. This antibody can
be applied in different methods to detect L. pneumophila (Yamaguchi
et al., 2017; Yanez et al., 2005), improving speciﬁcity of the method.
Continuing development by sourcing further monoclonal antibodies to
increase the range of detection, automatization, and further optimiza-
tion will improve the detection.
The prevention of legionellosis is a public health issue and requires
speciﬁc systems to control and detect these microorganisms. The dis-
covery of an antibody to speciﬁcally detect L. pneumophila would open
the door to the development of a simple rapid detection system. If the
antigen recognized is surface exposed, the protocol would be simpliﬁed
by the absence of sample manipulation, detecting intact cells. In the
coming years, the goal to reduce legionellosis is to minimize disease
transmission through risk assessment, regular maintenance of potable
and nonpotable water systems, and water monitoring and treatment
in facilities that care for susceptible populations (Sehulster et al.,
2003; Tablan et al., 2004).
The discovery of a speciﬁc sensitive antibody/cocktail antibody to all
L. pneumophila serogroups would allow the development of a speciﬁc
automated device for the detection and comprehensive surveillance ofontrol positive); B: L. pneumophila sg 8 in PBS; C: L. pneumophila sg 8 in 1% formalin.
(isolates that showed negative result with the LP3IIG2 antibody in the antibody assay).
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system based on an antibody would reduce the variability in the analy-
ses and also avoid thenonidentiﬁcation of viable but not culturable cells.
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